Stocktoria
Protagonist Therapeutics, Inc PTGX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-08-11
Protagonist Therapeutics, Inc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $46.0M | $434.4M | $60.0M | $26.6M | $27.4M |
| R&D expense | $159.3M | $138.1M | $120.2M | $126.2M | $126.0M |
| Operating income | -$158.1M | $252.8M | -$93.7M | -$131.4M | -$125.8M |
| Income tax | $838,000 | $4.2M | $0 | $0 | $0 |
| Net income | -$130.1M | $275.2M | -$79.0M | -$127.4M | -$125.6M |
| EPS (diluted) | $-2.05 | $4.23 | $-1.39 | $-2.60 | $-2.71 |
| Operating cash flow | $57.7M | $184.2M | -$70.2M | -$108.1M | -$107.9M |
| Free cash flow | $56.1M | $182.8M | -$70.8M | -$108.9M | -$109.0M |
| Cash & equivalents | $128.4M | $97.2M | $186.7M | $125.7M | $123.7M |
| Total assets | $668.2M | $744.7M | $358.0M | $247.9M | $347.7M |
| Total liabilities | $53.5M | $69.4M | $21.3M | $32.3M | $47.7M |
| Shareholders' equity | $614.7M | $675.3M | $336.7M | $215.6M | $300.0M |
Source: SEC EDGAR filings · CIK 0001377121 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.